Visão geral da empresa
A clinical-stage neuromuscular disease company, Dyne Therapeutics, Inc. is dedicated to the discovery and development of novel therapeutics specifically targeting neuromuscular diseases within the United States market. The enterprise operates within the Healthcare sector and the specialized Biotechnology industry, positioning it as a developer of a portfolio of muscle disease therapeutics that includes active programs in myotonic dystrophy type 1 and Duchenne muscular dystrophy. The company demonstrates a substantial market capitalization of $3.03B and employs a workforce of 258 individuals to execute its research and development initiatives. While the available financial data does not disclose annual revenue figures, the market cap of $3.03B indicates that the market assigns significant value to the company's intellectual property and pipeline potential despite the absence of traditional revenue generation in its current clinical-stage model.
Saúde financeira
The financial statements for Dyne Therapeutics, Inc. reflect a net income of $-446,214,016 and an EBITDA of $-466,135,008 over the trailing twelve-month period, while the company reports no revenue data available. The substantial negative net income relative to the zero revenue figure highlights a cost structure dominated by research, development, and operational expenditures typical of early-stage biotechnology firms that have not yet achieved commercial product launches. The company generates a free cash flow of $-260,087,008, indicating a continuous consumption of cash reserves to fund ongoing operations and clinical trials rather than generating internal liquidity. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, which is consistent with a business model where costs exceed revenues or where revenue is not yet recognized, resulting in no positive margin contribution. In terms of solvency, the company holds $1.11B in cash against total debt of $169.20M, supported by a debt-to-equity ratio of 17.41 and a current ratio of 22.25. The current ratio of 22.25 suggests an extremely conservative balance sheet regarding short-term liquidity, as the company possesses more than twenty-two times the current assets necessary to cover its current liabilities. Return on Equity stands at -55.7% and Return on Assets is -31.2%, metrics that reveal the company is currently utilizing shareholder and asset bases to generate negative returns due to heavy investment in R&D before any commercial profitability is realized.
Avaliação de valorização
Valuation multiples for Dyne Therapeutics, Inc. present a trailing P/E ratio that is not applicable (N/A) and a forward P/E of -6.06, implying that the market prices the stock based on future expectations of earnings that are currently negative and not yet positive. The price-to-book ratio is 3.12, indicating that the market values the company at more than three times its book value, which reflects a premium assigned to the company's intangible assets, clinical pipeline, and proprietary technology. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are reported as N/A and -4.49 respectively, suggesting that traditional sales-based or earnings-based valuation models are not currently applicable due to the lack of revenue and negative earnings. The stock has traded within a range defined by a 52-week high of $25.00 and a 52-week low of $6.36, providing a historical context for price volatility within the biotechnology sector. The beta value of 1.28 indicates that the stock's price volatility is higher than the broader market, moving 28% more than the market index on average during periods of fluctuation.
Growth & Income
The available data does not provide specific figures for revenue growth or earnings growth year-over-year, as these metrics are listed as N/A for this clinical-stage entity. Consequently, it is not possible to determine the rate of earnings growth relative to revenue growth, as the underlying revenue stream is currently not available for calculation. As a non-dividend payer, the company does not distribute a dividend yield or a payout ratio, meaning the 0.0% payout ratio reflects a strategy where all available earnings, or in this case, cash reserves, are reinvested into research and development efforts rather than distributed to shareholders. The overall growth and income profile is characterized by a reliance on external capital and cash reserves to fuel expansion, as the company prioritizes pipeline advancement over current profitability or income distribution.